Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer
HER2-positive advanced breast cancer treatment in 2020 - Cancer Treatment Reviews
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | NEJM
Medicines | Free Full-Text | The Changing Landscape of Breast Cancer: How Biology Drives Therapy | HTML
CLEOPATRA: Pertuzumab Ups Survival by 16 Months in HER2-Positive Breast Cancer
Cleopatra trial
Confirmatory Overall Survival Analysis of CLEOPATRA | Research To Practice
CLEOPATRA Protocol review & OS 분석결과. Study Title A Phase III, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Evaluate the Efficacy and. - ppt download
Expert Guidance on Selecting Treatment and Management Approaches in Metastatic Breast Cancer Jointly sponsored by the Annenberg Center for Health Sciences. - ppt download
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
Confirmatory Overall Survival Analysis of CLEOPATRA | Research To Practice
Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | NEJM
Pertuzumab with Trastuzumab and Docetaxel in Elderly Patients in the CLEOPATRA Study | Research To Practice
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results - The Breast
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | NEJM
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study - ESMO Open
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology
HER2 Therapies - HER2+ MBC - Module - HER2+ MBC Care - Oncology - Clinical Care Options
Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy
